Fisayo Andrew Olotu

Fisayo Andrew Olotu

Auto-generated profile, based on publicly available information

Fisayo Andrew Olotu

Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4001, South Africa

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LJLanlan Jing
Lanlan Jing
GWGaochan Wu
Gaochan Wu
XHXia Hao
Xia Hao
FOFisayo A. Olotu
Fisayo A. Olotu
DKDongwei Kang
Dongwei Kang
Peng ZhanPeng Zhan
Peng Zhan

29 August 2018 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
FOFisayo A. Olotu
Fisayo A. Olotu
Clement AgoniClement Agoni
Clement Agoni
EAEmmanuel Adeniji
Emmanuel Adeniji
MAMaryam Abdullahi
Maryam Abdullahi
Mahmoud SolimanMahmoud Soliman
Mahmoud Soliman

1 April 2018 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
MAMaryam Abdullahi
Maryam Abdullahi
FOFisayo A. Olotu
Fisayo A. Olotu
Mahmoud SolimanMahmoud Soliman
Mahmoud Soliman

3 January 2019 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
FAFarideh Badichi Akher
Farideh Badichi Akher
AFAbdolkarim Farrokhzadeh
Abdolkarim Farrokhzadeh
FOFisayo A. Olotu
Fisayo A. Olotu
Clement AgoniClement Agoni
Clement Agoni
Mahmoud SolimanMahmoud Soliman
Mahmoud Soliman
The influence of chirality on the therapeutic activities of drug molecules has remained an interesting subject matter in drug design. The recent identification of two chiral irreversible inhibitors with differential inhibitory activities towards oncogenic fibroblast growth factor receptor 4 (FGFR4) presented an avenue to investigate the underlying mechanisms that accounted for their disparate activities. Accordingly, the S-configured form (9g) exhibited ‘15 times’ potency than the corresponding R-configured (9h) form. Nonetheless, the big question remains how does chirality influence their inhibitory potencies? Therefore, in this study, we seek to provide useful insights into this interesting phenomenon using molecular dynamics simulations and free binding energy calculations. Interestingly, we observed that the inhibitory 9g activity correlates with a coordinated movement of the active site p-loop, as specifically induced by the S-configuration, which allowed the rotation of three dihedral angles; φ1(CNCO), φ2(CCC*N) and φ3(CCCC), thereby achieving optimal orientations suitable for interactions with crucial active site residues such as LEU473, LYS503, ASP641 and TYR643. Consequentially, while the 9h-bound FGFR4 active site was highly unstable, 9g exerted an inward pulling effect which accounted for active site stability and compactness. Also, the positional movement of 9h (R-configuration) at the active site was restricted, thereby preventing interactions with key residues. Moreover, 9g exhibited the most favorable binding as compared to 9h which showed a relatively lower ΔGbind. The higher binding affinity of 9g to FGFR4 can be mainly attributed to the increase in van der Waals energy by −4.12 kcal mol−1 and electrostatic by −2.89 kcal mol−1. The difference in van der Waals interactions is mainly determined by two residues; ASP641 and TYR643, whilst, the difference in electrostatic interactions is primarily determined by two residues LEU473 and LYS503.